Patents by Inventor Jon Cuccui
Jon Cuccui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11890336Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.Type: GrantFiled: November 16, 2020Date of Patent: February 6, 2024Assignee: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Madeleine Moule
-
Publication number: 20230241208Abstract: This invention relates to the use of S. pneumoniae protein antigens, such as NanA, PiuA and Sp0148, as carriers for immunogenic S. pneumoniae capsular polysaccharide. This may be useful for example in glycoconjugate vaccines able to generate a protective immune response against multiple capsular serotypes. Glycoconjugates, vaccine compositions and methods of manufacture and use are provided.Type: ApplicationFiled: May 2, 2019Publication date: August 3, 2023Inventors: Brendan WREN, Jeremy BROWN, Jon CUCCUI
-
Patent number: 11365401Abstract: The disclosure relates to an oligosaccharyltransferase polypeptides and their use in the synthesis of glycoconjugates in bacterial cells; vaccines and immunogenic compositions comprising said glycoconjugates and their use in the prevention and/or treatment of bacterial infection. Bacterial expression system comprising said oligosaccharyltransferase polypeptides are also disclosed.Type: GrantFiled: March 14, 2018Date of Patent: June 21, 2022Assignee: London School of Hygiene and Tropical MedicineInventors: Jon Cuccui, Brendan Wren
-
Patent number: 11278610Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.Type: GrantFiled: March 17, 2020Date of Patent: March 22, 2022Assignee: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Sherif Abouelhadid
-
Patent number: 11179454Abstract: The disclosure relates to attenuated bacterial cells expressing glycans and glycoconjugate antigens and their use in the manufacture of whole cell vaccines effective at preventing or treating bacterial infections in non-human species.Type: GrantFiled: March 14, 2018Date of Patent: November 23, 2021Assignee: London School of Hygiene and Tropical MedicineInventors: Jon Cuccui, Brendan Wren, Alexandra Faulds-Pain
-
Publication number: 20210069312Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.Type: ApplicationFiled: November 16, 2020Publication date: March 11, 2021Applicant: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Madeleine Moule
-
Publication number: 20200215178Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.Type: ApplicationFiled: March 17, 2020Publication date: July 9, 2020Applicant: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Sherif Abouelhadid
-
Patent number: 10646562Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.Type: GrantFiled: February 9, 2018Date of Patent: May 12, 2020Assignee: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Sherif Abouelhadid
-
Publication number: 20200054732Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.Type: ApplicationFiled: September 11, 2017Publication date: February 20, 2020Applicant: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Madeleine Moule
-
Publication number: 20200032226Abstract: The disclosure relates to an oligosaccharyltransferase polypeptides and their use in the synthesis of glycoconjugates in bacterial cells; vaccines and immunogenic compositions comprising said glycoconjugates and their use in the prevention and/or treatment of bacterial infection. Bacterial expression system comprising said oligosaccharyltransferase polypeptides are also disclosed.Type: ApplicationFiled: March 14, 2018Publication date: January 30, 2020Applicant: London School of Hygiene and Tropical MedicineInventors: Jon Cuccui, Brendan Wren
-
Publication number: 20200009241Abstract: The disclosure relates to attenuated bacterial cells expressing glycans and glycoconjugate antigens and their use in the manufacture of whole cell vaccines effective at preventing or treating bacterial infections in non-human species.Type: ApplicationFiled: March 14, 2018Publication date: January 9, 2020Applicant: London School of Hygiene and Tropical MedicineInventors: Jon Cuccui, Brendan Wren, Alexandra Faulds-Pain
-
Patent number: 10039814Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.Type: GrantFiled: March 21, 2017Date of Patent: August 7, 2018Assignee: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Madeleine Moule
-
Publication number: 20180169212Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.Type: ApplicationFiled: February 9, 2018Publication date: June 21, 2018Applicant: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Sherif Abouelhadid
-
Patent number: 9931392Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.Type: GrantFiled: January 17, 2014Date of Patent: April 3, 2018Assignee: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Sherif Abouelhadid
-
Publication number: 20170196958Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.Type: ApplicationFiled: March 21, 2017Publication date: July 13, 2017Applicant: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Madeleine Moule
-
Patent number: 9642902Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.Type: GrantFiled: January 21, 2014Date of Patent: May 9, 2017Assignee: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Madeleine Moule
-
Publication number: 20150344928Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.Type: ApplicationFiled: January 17, 2014Publication date: December 3, 2015Applicant: London School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Sherif Abouelhadid
-
Publication number: 20150328301Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.Type: ApplicationFiled: January 21, 2014Publication date: November 19, 2015Applicant: Londong School of Hygiene and Tropical MedicineInventors: Brendan Wren, Jon Cuccui, Madeleine Moule
